How GLP-1 and Dual GIP/GLP-1 Drugs Work Across Your Body — A Mechanistic Guide
GIP and GLP-1 have complementary effects across the brain, pancreas, and fat tissue, explaining why dual agonists like tirzepatide outperform single GLP-1 drugs for diabetes and obesity.
Quick Facts
What This Study Found
This review maps out how the two incretin hormones — GIP and GLP-1 — work across multiple organ systems and why combining their actions in dual agonist drugs produces superior metabolic effects. Key mechanistic differences include: both suppress appetite through brain satiety centers, both stimulate insulin from beta cells, but they diverge on glucagon — GIP promotes glucagon release during low blood sugar (protective against hypoglycemia) while GLP-1 suppresses glucagon during high blood sugar. On fat metabolism, GIP directly promotes fat storage in appropriate tissue while GLP-1 indirectly promotes fat breakdown, and together they maintain healthy fat distribution, reduce ectopic fat, and boost adiponectin secretion.
This complementary biology explains why dual GIP/GLP-1 agonists like tirzepatide can achieve greater weight loss and metabolic improvement than GLP-1-only drugs, while the GIP component provides a safety buffer against hypoglycemia.
Key Numbers
2 incretin hormones (GIP and GLP-1) · Multiple tissue targets: brain, pancreatic β-cells, α-cells, adipocytes · Complementary effects on glucagon: glucagonotropic (GIP) vs glucagonostatic (GLP-1)
How They Did This
This is a narrative review published in Frontiers in Endocrinology that synthesizes published research on the cellular and molecular mechanisms of GIP and GLP-1 signaling across multiple tissues. The author reviews the pharmacology of approved GLP-1 and dual GIP/GLP-1 receptor agonists and their clinical trial outcomes in type 2 diabetes, obesity, and cardiovascular disease.
Why This Research Matters
Understanding why dual agonists outperform single GLP-1 agonists is crucial as the field moves toward triple agonists and next-generation metabolic drugs. This review provides the mechanistic roadmap: GIP and GLP-1 are not redundant — they have complementary and sometimes opposing effects that together create a more balanced metabolic intervention. This knowledge guides the development of future drugs with better efficacy and fewer side effects.
The Bigger Picture
The incretin field is evolving rapidly from single GLP-1 agonists to dual agonists (GIP/GLP-1) and now triple agonists (GIP/GLP-1/glucagon). Understanding how each component contributes to metabolic improvement is essential for rational drug design. This review provides the mechanistic foundation for that progression, explaining why more receptor targets don't just mean more of the same effect — they create qualitatively different and potentially superior metabolic outcomes.
What This Study Doesn't Tell Us
As a narrative review by a single author, it reflects one perspective on the literature rather than a systematic synthesis. Some mechanistic details are derived from preclinical studies that may not fully translate to humans. The review does not provide quantitative comparisons between specific drugs or detail their side effect profiles. Rapidly evolving clinical trial data means some conclusions may already be outdated.
Questions This Raises
- ?Could selective GIP agonists alone have therapeutic value for specific metabolic conditions, or does GIP only shine in combination with GLP-1?
- ?How will triple agonists (adding glucagon receptor activation) change the benefit-harm balance compared to dual agonists?
- ?Do the complementary effects of GIP and GLP-1 on fat metabolism explain why tirzepatide produces more favorable body composition changes than semaglutide?
Trust & Context
- Key Stat:
- Complementary, not redundant GIP and GLP-1 have opposing effects on glucagon and fat metabolism, which is why combining them produces better results than either alone
- Evidence Grade:
- This is a narrative review in a respected endocrinology journal, providing a comprehensive synthesis of molecular, preclinical, and clinical evidence. While reviews do not generate new data, this one effectively organizes the mechanistic understanding underpinning one of the most important drug classes in modern medicine.
- Study Age:
- Published in 2024, this is a very current review capturing the latest understanding of incretin biology at a time when dual and triple agonists are reshaping metabolic medicine.
- Original Title:
- Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists.
- Published In:
- Frontiers in endocrinology, 15, 1431292 (2024)
- Authors:
- Liu, Qiyuan Keith
- Database ID:
- RPEP-08752
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What's the difference between GLP-1 drugs and dual GIP/GLP-1 drugs?
GLP-1-only drugs (like semaglutide/Ozempic) activate one gut hormone receptor. Dual agonists like tirzepatide (Mounjaro/Zepbound) activate both GIP and GLP-1 receptors. Because these two hormones have complementary effects — different actions on glucagon, fat storage, and fat burning — dual agonists can produce greater weight loss and metabolic improvement while maintaining a natural safety buffer against low blood sugar.
Why does GIP help prevent hypoglycemia?
GIP has a unique 'smart' effect on glucagon, the hormone that raises blood sugar. When blood sugar drops too low, GIP promotes glucagon release to bring it back up. GLP-1, by contrast, suppresses glucagon when blood sugar is high. Together in a dual agonist, they create a balanced system that lowers high blood sugar without causing dangerous drops — a significant safety advantage.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-08752APA
Liu, Qiyuan Keith. (2024). Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists.. Frontiers in endocrinology, 15, 1431292. https://doi.org/10.3389/fendo.2024.1431292
MLA
Liu, Qiyuan Keith. "Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists.." Frontiers in endocrinology, 2024. https://doi.org/10.3389/fendo.2024.1431292
RethinkPeptides
RethinkPeptides Research Database. "Mechanisms of action and therapeutic applications of GLP-1 a..." RPEP-08752. Retrieved from https://rethinkpeptides.com/research/liu-2024-mechanisms-of-action-and
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.